View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM 1045

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM 977

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent Office Issues Notice of Intention to Grant European Patent

🕔10/18/2018 9:11:57 AM 1153

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM 2368

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM 1857

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM 1808

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Cancer Vaccine

🕔7/30/2018 9:45:25 AM 2445

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔7/25/2018 10:00:00 AM 1907

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Office to Allow Key Patent for Progenza

🕔7/10/2018 9:01:37 AM 2351

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.

Read Full Article

Regeneus Ltd (ASX:RGS) Update on Licensing Progenza in Japan

🕔7/3/2018 10:00:36 AM 1967

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.

Read Full Article
###

9,658 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 177) (Last 30 Days: 950) (Since Published: 44493) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media